By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and 7 years without generic competition for remdesivir, its experimental coronavirus treatment.
Read more on NPR
Thursday, 26 March 2020
loobobilly News: Drugmaker Asks FDA To Rescind Rare Disease Status, Perks For COVID-19 Drug
Labels:
Business
,
loobobillyNPR
By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and 7 years without generic competition for remdesivir, its experimental coronavirus treatment.
Read more on NPR
Do You Like This Article
Get Subscribe to Free Email Updates!!
Popular Posts
-
History has witnessed some of the most outstanding achievements by men and women in due course of time. However, the achievement is e...
-
The Dark Side Of The Recovery Revealed In Big Data The way the government tracks recessions is largely the same as it was 70 years ago. A re...
-
Iowa College Becomes Battleground For Student Worker Unionization Students with campus jobs at Grinnell College want to unionize, but the co...
-
Why we'll probably see avocado prices rise soon in the U.S. Earlier this week, the U.S. Department of Agriculture put a temporary suspen...
-
The Iranian Revolution, 40 Years Later How have the events of 1979 affected today’s politics? How have the events of 1979 affected today’s p...
-
There Are Lots Of Antibiotics In The Beef Supply. McDonald's Vows To Change This The fast-food giant, one of the world's biggest bee...
-
Longtime Trump accountant says a decade of financial statements are unreliable Mazars USA, the longtime accountants to Donald Trump and the ...
